

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

1st April 2025

Company: Chordia Therapeutics, Inc
 Representative: Chief Executive Officer Hiroshi Miyake
 (Security Code: 190A TSE Growth Market)
 Contact: IR Representative Ami Kira

Presentation of data from our pipeline
at the American Association for Cancer Research Annual Meeting 2025

Kanagawa Japan

1st April 2025 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake) announces that Chordia will present new data at the American Association for Cancer Research (AACR) Annual Meeting, April 25-30, 2025, in Chicago, Illinois.

Two presentations will be given on Chordia's pipeline of CDK12 inhibitor CTX-439, and a GCN2 inhibitor.

Planned presentation on CTX-439, CDK12 inhibitor

Abstract No	1636
Title	Novel CDK12/13 inhibitor CTX-439 downregulates MCL1 via transcriptional mRNA read-through and synergistically acts with BCL-XL inhibitors for cancer therapy
Session No	Poster
Time	April 28, 2025, 9:00 AM - 12:00 PM

Planned presentation on GCN2 inhibitor

Abstract No	1745
Title	Combining HRI/PERK/GCN2 inhibitor CRD-799 with proteasome inhibitors provides a novel approach to overcoming resistance in multiple myeloma treatment
Session No	Poster
Time	April 28, 2025, 9:00 AM - 12:00 PM

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research of several preclinical assets, including

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

ir@chorditherapeutics.com



CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors. For more information, please contact our website <https://www.chorditherapeutics.com/en/>.